To the Editor.—
The article describing clinical experience with clonidine hydrochloride as an alternative to haloperidol for the treatment of Gilles de la Tourette syndrome (TS) (Archives 1980;37:1350-1357), as well as the genetic and biochemical studies emanating from the Yale group, is a substantial contribution to the literature. However, we believe that several issues raised in this article warrant discussion.Gilles de la Tourette syndrome is defined by the authors as a "severe neuropsychiatric syndrome of childhood onset and lifelong duration that consists of multiform motor and phonic tics and other behavioral and psychological symptoms." It is conceptualized as a neuropsychiatric dysfunction that affects the regulation of impulses, thoughts, motor activities, speech, and complex actions... a disorder of psychomotor inhibition with a more or less pervasive impact and with varied and individualistic symptom profiles ranging from chronic tics through disabling compulsions, irritability, and attentional and learning difficulties, as well as
Shapiro AK, Shapiro E. Clonidine and Haloperidol in Gilles de la Tourette Syndrome. Arch Gen Psychiatry. 1981;38(10):1183–1184. doi:10.1001/archpsyc.1981.01780350117015
Psychiatry in JAMA: Read the Latest
Customize your JAMA Network experience by selecting one or more topics from the list below.